drugset / Trial / NCT02730962

Interventional Bioremediation of Microbiota in Metabolic Syndrome

NCT02730962

Phase 2 Terminated 12 enrolled University of Minnesota
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether changing the microbial composition in the colon can improve metabolism of sugar in people who are on the verge of developing diabetes (pre-diabetics). Study participants will undergo a fecal microbiota transplantation (FMT) using material from lean donors, as well as a series of tests prior to and after the transplant. The investigators will examine any changes in fecal bacterial composition associated with FMT and determine if any observed changes have an influence on blood sugar metabolism.

Timeline

Start
2016-06
Primary completion
2018-01
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Clindamycin Unknown 300 mg Oral
Subject Neomycin Unknown 1000 mg Oral
Subject Vancomycin Other / unclassified 500 mg Oral

Indications